OTCM
CFOR
Market cap46mUSD
Sep 11, Last price
4.60USD
1D
0.00%
1Q
130.05%
Jan 2017
-100.00%
IPO
-100.00%
Name
OpGen Inc
Chart & performance
P/E
1.98
P/S
1.55
EPS
2.33
Div yield, %
—
Shrs. gr., 5y
163.99%
Rev. gr., 5y
48.27%
Revenues
30m
+481.20%
Net income
24m
+96.95%
CFO
-1m
L-75.69%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CapForce Inc. is a precision medicine company dedicated to developing and commercializing sophisticated molecular microbiology solutions. Its mission is to address life-threatening infectious diseases for patients in the United States and across international markets. The company's diverse product range includes Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel diagnostic tests, and SARS CoV-2 testing kits. Beyond its product line, CapForce extends its offerings to include laboratory services, collaboration services (such as funded software arrangements), and licensing agreements. Additionally, the company provides listing sponsorship and consultancy services. Formerly known as OpGen, Inc., the entity officially changed its name to CapForce Inc. in February 2026. CapForce Inc. was established in 2001 and maintains its headquarters in Clarksburg, Maryland.
Key people
Vadim M Sapiro
Chief Information Officer · since 2011
Prabhavathi Fernandes
Director · since 2020
Director · since 2020
Independent Director · since 2019
David M Rubin
Independent Director · since 2015
Misti Ushio
Independent Director · since 2012
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
23219 Stringtown Road
Suite 300
Clarksburg, MD 20871
US
Suite 300
Clarksburg, MD 20871
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||